The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.
Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions Read More »
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough Read More »
Spending on the tests, which analyze genetic material from both people and pathogens, rose 20% year over year in 2024, the analysis found.
Genetic testing takes greater share of Medicare Part B test spending: OIG Read More »
Un paciente con ceguera total causada por un daño irreversible en el nervio óptico ha recuperado parcialmente la visión natural tras participar en un ensayo clínico de estimulación eléctrica de la corteza visual. El caso, observado en el marco de un estudio …
En una investigación reciente, se ha analizado en detalle el efecto que los microplásticos de polihidroxibutirato-co-valerato (PHBV) tienen en un diminuto crustáceo, vital en los ecosistemas hipersalinos. Los citados microplásticos son biopolímeros que están …
Descubren que algunos crustáceos obtienen energía de microplásticos biodegradables Read More »
Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue Up 46% in Q4 Read More »
Rep. Jake Auchincloss of Massachusetts said the Commissioner’s National Priority Voucher program did not receive congressional backing. The FDA has also not yet made disclosures for eight senior reviewers, according to Auchincloss.
FDA’s Commissioner’s Priority Voucher Program ‘Shrouded in Secrecy,’ Democratic Rep Says Read More »
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity Read More »
After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the FDA on January 28 that they would not pull the drug.
Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos Read More »
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods Read More »
